You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恒生沪深港创新药指数纳入百济神州、信达、康龙化成 剔出中生制药、联邦制药等
阿思达克 11-19 16:46
恒指公司公布恒生沪深港创新药精选50指数截至10月31日止的半年度指数检讨结果,新增及剔出各12只股份,有关变动将於12月7日(星期一)起生效。

恒生沪深港创新药精选50指数将加入港股信达生物(01801.HK)、康龙化成(03759.HK)及百济神州(06160.HK),并剔出中生制药(01177.HK)、方达控股(01521.HK)及联邦制药(03933.HK)。

A股方面,该指数将纳入上海现代制药(600420.SH)、山东鲁抗医药(600789.SH)、华东医药(000963.SZ)、上海科华生物(002022.SZ)、四川科伦药业(002422.SZ)、安徽安科生物(300009.SZ )、深圳翰宇药业(300199.SZ )、迪瑞医疗科技(300396.SZ)及深圳康泰生物(300601.SZ)。

该指数并将剔除浙江医药股(600216.SH)、普洛药业(000739.SZ)、山东新华制药(000756.SZ)、浙江仙琚制药(002332.SZ)、海思科医药(002653.SZ)、乐普北京医疗器械(300003.SZ)、迈克生物(300463.SZ)、万孚生物技术(300482.SZ)及海南普利制药(300630.SZ)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account